(Q43272944)

18 November 2017

title

Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study (English)

1 reference

18 November 2017

Julio C Delgado

1

1 reference

18 November 2017

Igor Y Pavlov

series ordinal

2

1 reference

18 November 2017

Fuad S Shihab

series ordinal

3

1 reference

18 November 2017

publication date

20 September 2009

1 reference

18 November 2017

published in

Transplant Immunology

1 reference

18 November 2017

volume

22

1 reference

18 November 2017

issue

1-2

1 reference

18 November 2017

page(s)

1-4

1 reference

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

CD30-mediated signaling promotes the development of human T helper type 2-like T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

CD30, a marker to detect the high-risk kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Association of Elevated Pretransplant sCD30 Levels With Graft Loss in 206 Patients Treated With Modern Immunosuppressive Therapies After Renal Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Soluble CD30 as a predictor of kidney graft outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Kidney graft recipients with pretransplantation HLA CLASS I antibodies and high soluble CD30 are at high risk for graft loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Prognostic values of soluble CD30 and CD30 gene polymorphisms in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Elevated soluble CD30 correlates with development of bronchiolitis obliterans syndrome following lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Elevated pretransplantation soluble CD30 is associated with decreased early allograft function after human lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Level of soluble CD30 after kidney transplantation correlates with acute rejection episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Association between serum soluble CD30 and serum creatinine before and after renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Value of soluble CD30 in liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2009.09.006

10.1016/J.TRIM.2009.09.006

7 January 2021

Identifiers

DOI

1 reference

18 November 2017

1 reference